New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For FFIV;CREE;TPX;MDRX;ISRG From The Last 14 Days
Check below for free stories on FFIV;CREE;TPX;MDRX;ISRG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 21, 2014
13:00 EDTISRGIntuitive Surgical receives FireFly FDA clearance for Vinci Xi system
Subscribe for More Information
09:51 EDTCREEChina denies plans for raising LED tariffs, LEDinside reports
Subscribe for More Information
August 20, 2014
10:04 EDTFFIVOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:32 EDTFFIVF5 Networks upgraded at ISI Group
As noted earlier, ISI Group upgraded F5 Networks to Strong Buy from Buy. The firm thinks the company's positioning vis-a-vis NFN/SDN has improved, while its momentum from a number of growth drivers, including security, has increased. The firm is now more confident that the company's EPS could approach $7 in 2015. Target $135.
07:51 EDTMDRXAllscripts has reached attractive entry point, says RBC Capital
Subscribe for More Information
August 19, 2014
21:06 EDTFFIVF5 Networks upgraded to Strong Buy from Buy at ISI Group
11:05 EDTFFIVImperva seen as takeover candidate under new CEO
Subscribe for More Information
08:42 EDTFFIVImperva new CEO has history of selling companies, says Sterne Agee
After Imperva (IMPV) appointed Anthony Bettencourt as its new CEO, Sterne Agee says that he has a history of selling companies. The firm believes that Imperva "would likely be an acquisition candidate" for a number of large tech companies such as Cisco (CSC), Juniper (JNPR), HP (HPQ), IBM (IBM), Check Point (CHKP), or F5 (FFIV). Sterne Agee believes that Imperva could be acquired for as much as $45 per share, and it keeps a Buy rating on the stock.
August 18, 2014
10:57 EDTCREEOptions with decreasing implied volatility
Subscribe for More Information
06:06 EDTCREECree implied volatility of 28 at lower end of index mean range
Subscribe for More Information
August 15, 2014
10:20 EDTMDRXAllscripts management to meet with Maxim
Subscribe for More Information
August 14, 2014
07:33 EDTMDRXAllscripts sell-off creates attractive entry point, says Jefferies
Subscribe for More Information
06:35 EDTMDRXAllscripts volatility flat on wide price movement
Allscripts September call option implied volatility is at 32, December is at 33; compared to its 26-week average of 32 according to Track Data, suggesting non-directional price movement.
06:08 EDTCREECree implied volatility of 30 at lower end of index mean range
Subscribe for More Information
August 13, 2014
16:11 EDTMDRXAllscripts expands partnership with Clinical Architecture
Subscribe for More Information
10:01 EDTCREEOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: CSR (CSRE) downgraded to Hold from Buy at Jefferies... Celadon Group (CGI) downgraded to Equal Weight from Overweight at Stephens... Cree (CREE) downgraded to Hold from Buy at Summit Research... Crestwood Equity (CEQP) downgraded to Underweight from Equal Weight at Barclays... Intrepid Potash (IPI) downgraded to Sell from Hold at BGC Financial... JDSU (JDSU) downgraded to Neutral from Buy at B. Riley... King Digital (KING) downgraded to Equal Weight from Overweight at Barclays... Marin Software (MRIN) downgraded to Neutral from Buy at Goldman... Mosaic (MOS) downgraded to Sell from Hold at BGC Financial... Potash (POT) downgraded to Sell from Hold at BGC Financial... Regado Biosciences (RGDO) downgraded to Market Perform from Outperform at Cowen... Southern Company (SO) downgraded to Underweight from Equal Weight at Morgan Stanley... StarTek (SRT) downgraded to Equal Weight from Overweight at First Analysis... Tuniu (TOUR) downgraded to Neutral from Outperform at Credit Suisse.
09:15 EDTCREEOn The Fly: Pre-market Movers
Subscribe for More Information
08:17 EDTCREECree price target lowered to $64 from $77 at Canaccord
Subscribe for More Information
08:12 EDTCREECree downgraded to Hold from Buy at Summit Research
Summit Research downgraded Cree to Hold following the Q4 report and guidance citing gross margin pressures. Price target is $40.
07:01 EDTCREE, CREECree downgraded to Underperform from Outperform at CLSA
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use